CLC number: R285
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2020-02-22
Cited: 0
Clicked: 3542
Cong-Ying Song, Ying-Ge Xu, Yuan-Qiang Lu. Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects[J]. Journal of Zhejiang University Science B, 2020, 21(4): 280-290.
@article{title="Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects",
author="Cong-Ying Song, Ying-Ge Xu, Yuan-Qiang Lu",
journal="Journal of Zhejiang University Science B",
volume="21",
number="4",
pages="280-290",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1900607"
}
%0 Journal Article
%T Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects
%A Cong-Ying Song
%A Ying-Ge Xu
%A Yuan-Qiang Lu
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 4
%P 280-290
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1900607
TY - JOUR
T1 - Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects
A1 - Cong-Ying Song
A1 - Ying-Ge Xu
A1 - Yuan-Qiang Lu
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 4
SP - 280
EP - 290
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1900607
Abstract: Tripterygium wilfordii Hook F has significant anti-inflammatory and immunosuppressive properties and is widely used for treating autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and kidney disease, especially in traditional Chinese medicine. The mechanisms underlying its effects may be diverse but they remain unclear, and its toxicity and side effects limit its wider clinical application. This review summarizes the clinical application of Tripterygium wilfordii Hook F in recent years, as well as the results of studies into its mechanisms and toxicity, to provide a reference for its future clinical application.
[1]Boorsma CE, Draijer C, Melgert BN, 2013. Macrophage heterogeneity in respiratory diseases. Mediators Inflamm, 2013:769214.
[2]Cao LJ, Yan M, Li HD, et al., 2015. Progress on mechanism of Tripterygium wilfordii-induced liver injury and detoxification mechanism of licorice. China J Chin Mat Med, 40(13):2537-2541 (in Chinese).
[3]Chen H, Cao F, Li X, et al., 2015. Clinical effect of mycophenolate mofetil and tripterygium glycosides on refractory nephrotic syndrome and the influence of renal function. Chin J Diffic Compl Cases, 14(4):363-365 (in Chinese).
[4]Chen QX, 2015. Effects of different processing methods on the toxic components of Tripterygium wilfordii. Chin J Clin Rational Drug Use, (29):103-104 (in Chinese).
[5]https://doi.org/10.15887/j.cnki.13-1389/r.2015.29.067
[6]Chen X, Murakami T, Oppenheim JJ, et al., 2005. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood, 106(7):2409-2416.
[7]Du JL, Cui MH, Su ZW, et al., 2008. Effects of compatibility of Tripterygium wilfordii Hook and licorice on biochemical indexes in rats. J Pract Tradit Chin Int Med, 22(5):71-72 (in Chinese).
[8]Feng MX, Li YN, Ruan WS, et al., 2018. Predictive value of the maximum serum creatinine value and growth rate in acute paraquat poisoning patients. Sci Rep, 8(1):11587.
[9]Gao S, Wake H, Gao Y, et al., 2019. Histidine-rich glycoprotein ameliorates endothelial barrier dysfunction through regulation of NF-κB and MAPK signal pathway. Br J Pharmacol, 176(15):2808-2824.
[10]Gu YW, Chen JS, Yang M, et al., 2018. Research advances in preparations of Tripterygium wilfordii for external use. Pharm Care Res, 18(1):33-37 (in Chinese).
[11]Han R, Rostami-Yazdi M, Gerdes S, et al., 2012. Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol, 74(3):424-436.
[12]He YM, Yao YY, Chen YL, et al., 2017. Research progress of Tripterygium wilfordii preparations. China Pharm, 28(4):551-554 (in Chinese).
[13]Hong YZ, Zhou WD, Li K, et al., 2002. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney Int, 62(4):1291-1300.
[14]Hu PY, Li ZL, Pu SB, et al., 2013. Research advances on Triptreygium wilfordii. Chin Wild Plant Resour, 32(2):1-3 (in Chinese).
[15]Ji SM, Wang QW, Yin G, et al., 2007. Outcome of 5 years of immunosuppression with Tripterygium wilfordii Hook F in renal allograft transplant recipients. J Med Postgr, 20(1):53-57 (in Chinese).
[16]Jiang M, Liu XH, Zhang DH, et al., 2018. Celastrol treatment protects against acute ischemic stroke-induced brain injury by promoting an IL-33/ST2 axis-mediated microglia/ macrophage M2 polarization. J Neuroinflammation, 15(1):78.
[17]Lamkanfi M, Dixit VM, 2014. Mechanisms and functions of inflammasomes. Cell, 157(5):1013-1022.
[18]Lee S, Vasudevan S, 2013. Post-transcriptional stimulation of gene expression by microRNAs. In: Chan EKL, Fritzler MJ (Eds.), Ten Years of Progress in GW/P Body Research. Springer, New York, p.97-126.
[19]Li GW, Ren JA, Wang GF, et al., 2014. T2 enhances in situ level of Foxp3+ regulatory cells and modulates inflammatory cytokines in Crohn’s disease. Int Immunopharmacol, 18(2):244-248.
[20]Li H, Liu ZH, Dai CS, et al., 2002. Triptolide inhibits proinflammatory factor-induced over-expression of class II MHC and B7 molecules in renal tubular epithelial cells. Acta Pharmacol Sin, 23(9):775-781.
[21]Li J, Shen FH, Guan CW, et al., 2014. Activation of Nrf2 protects against triptolide-induced hepatotoxicity. PLoS ONE, 9(7):e100685.
[22]Li Y, Yu C, Zhu WM, et al., 2010. Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17. Mol Immunol, 47(15):2467-2474.
[23]Li Y, Tian Y, Zhu WM, et al., 2013. Triptolide induces suppressor of cytokine signaling-3 expression and promotes lamina propria mononuclear cells apoptosis in Crohn’s colitis. Int Immunopharmacol, 16(2):268-274.
[24]Li YS, Tong PJ, Ma HZ, et al., 2006. Toxicity attenuation and efficacy potentiation effect of liquorice on treatment of rheumatoid arthritis with Tripterygium wilfordii. Chin J Integr Tradit West Med, 26(12):1117-1119 (in Chinese).
[25]Liang Y, Zhang XL, Liu B, et al., 2019. Curative effect of tripterygium glycosides combined with irbesartan on IgA nephropathy with increased urinary podocyte excretion. Chin Gen Pract, 22(12):1426-1431 (in Chinese).
[26]https://doi.org/10.12114/j.issn.1007-9572.2018.00.403
[27]Liao NS, Ren JA, Fan CG, et al., 2009. Efficacy of polyglycosides of Tripterygium wilfordii in preventing postoperative recurrence of crohn disease. Chin J Gastrointest Surg, 12(2):167-169 (in Chinese).
[28]Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al., 2012. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol, 107(7):1051-1063.
[29]Liu Q, Chen T, Chen G, et al., 2007. Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-κB pathways. Mol Immunol, 44(10):2686-2696.
[30]Liu QY, Chen TY, Chen HB, et al., 2004. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation. Biochem Biophys Res Commun, 319(3):980-986.
[31]Liu W, Yan L, Zhu Q, et al., 2014. Therapeutic effect of tripterygium glycosides plus prednisone on moderate active systemic lupus erythematosus. J Chin Pract Diagn Ther, 28(12):1234-1235 (in Chinese).
[32]https://doi.org/10.13507/j.issn.1674-3474.2014.12.038
[33]Lu YQ, 2018. HIV and paraquat poisoning: fighting fire with fire? J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(2):168-170.
[34]Luo D, Guo YM, Cheng Y, et al., 2017. Natural product celastrol suppressed macrophage M1 polarization against inflammation in diet-induced obese mice via regulating Nrf2/HO-1, MAP kinase and NF-κB pathways. Aging (Albany NY), 9(10):2069-2082.
[35]https://doi.org/10.18632/aging.101302
[36]Lv M, Deng JW, Tang N, et al., 2018. Efficacy and safety of Tripterygium wilfordii Hook F on psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med, 2018: 2623085.
[37]Lv QW, Zhang W, Shi Q, et al., 2015. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA):a randomised, controlled clinical trial. Ann Rheum Dis, 74(6):1078-1086.
[38]Ma Z, Zhang Y, Liang MX, 2014. Toxicity reducing and efficacy enhancing research on rheumatoid arthritis effect of tripterygium compatible with licorice. Asia Pac Tradit Med, 10(8):9-11 (in Chinese).
[39]Ma ZJ, Dong JM, Wang JB, et al., 2017. Compatibility attenuated research of Glycyrrhiza concocted Tripterygium wilfordii based on high content analysis. Mod Chin Med, 19(11):1562-1565 (in Chinese).
[40]https://doi.org/10.13313/j.issn.1673-4890.2017.11.013
[41]Mei ZN, Li XK, Wu QR, et al., 2005. The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharmacol Res, 51(4):345-351.
[42]Middleton J, Americh L, Gayon R, et al., 2004. Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther, 6(2):60-72.
[43]Murray PJ, 2017. Macrophage polarization. Annu Rev Physiol, 79:541-566.
[44]Ng SC, Lam YT, Tsoi KKF, et al., 2013. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther, 38(8):854-863.
[45]Opal SM, van der Poll T, 2015. Endothelial barrier dysfunction in septic shock. J Intern Med, 277(3):277-293.
[46]Phatak UP, Alper A, Pashankar DS, 2019. Complementary and alternative medicine use in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr, 68(2):157-160.
[47]Ren JN, Tao QS, Wang XB, et al., 2007. Efficacy of T2 in active Crohn’s disease: a prospective study report. Dig Dis Sci, 52(8):1790-1797.
[48]Shang AD, Lu YQ, 2015. A case report of severe paraquat poisoning in an HIV-positive patient: an unexpected outcome and inspiration. Medicine (Baltimore), 94(8):e587.
[49]Shi JJ, Gao WQ, Shao F, 2017. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci, 42(4):245-254.
[50]Song SP, Li B, Wu ML, 2014. Empirical study on complex prescription leigongteng decoction attenuation synergistic action in degenerative nephritis rat kidney. Int J Tradit Chin Med, 36(3):223-227 (in Chinese).
[51]Stefater JA III, Ren SY, Lang RA, et al., 2011. Metchnikoff’s policemen: macrophages in development, homeostasis and regeneration. Trends Mol Med, 17(12):743-752.
[52]Strowig T, Henao-Mejia J, Elinav E, et al., 2012. Inflammasomes in health and disease. Nature, 481(7381):278-286.
[53]Sun T, Li X, Song H, et al., 2017. MiR-146a aggravates LPS-induced inflammatory injury by targeting CXCR4 in the articular chondrocytes. Cell Physiol Biochem, 44(4):1282-1294.
[54]Tao QS, Ren JA, Ji ZL, et al., 2009. Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease. Chin J Gastrointest Surg, 12(5):491-493 (in Chinese).
[55]von Moltke J, Ayres JS, Kofoed EM, et al., 2013. Recognition of bacteria by inflammasomes. Annu Rev Immunol, 31: 73-106.
[56]Wang HR, Pan J, Shang AD, et al., 2017. Time-dependent haemoperfusion after acute paraquat poisoning. Sci Rep, 7(1):2239.
[57]Wang XY, Zu YY, Huang L, et al., 2017. Treatment of rheumatoid arthritis with combination of methotrexate and Tripterygium wilfordii: a meta-analysis. Life Sci, 171:45-50.
[58]Wang YT, Gao BS, Yao LY, et al., 2015. The effect of tripterygium glycosides on early rejection after kidney transplantation. Chin J Gerontol, 35(21):6190-6191 (in Chinese).
[59]Wu F, Han M, Wilson JX, 2009. Tripterine prevents endothelial barrier dysfunction by inhibiting endogenous peroxynitrite formation. Br J Pharmacol, 157(6):1014-1023.
[60]Wu R, Li Y, Guo Z, et al., 2013. Triptolide ameliorates ileocolonic anastomosis inflammation in IL-10 deficient mice by mechanism involving suppression of miR-155/ SHIP-1 signaling pathway. Mol Immunol, 56(4):340-346.
[61]Xin WY, Wang QY, Zhang D, et al., 2017. A new mechanism of inhibition of IL-1β secretion by celastrol through the NLRP3 inflammasome pathway. Eur J Pharmacol, 814: 240-247.
[62]Xiong Y, Yan YL, Li YZ, 2018. Tripterine alleviates LPS-induced inflammatory injury by up-regulation of miR-146a in HaCaT cells. Biomed Pharmacother, 105:798-804.
[63]Xu B, Jiang MZ, Chu Y, et al., 2018. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J Hepatol, 68(4):773-782.
[64]Xu YG, Lu YQ, 2019. Systematic review and meta-analysis of the efficacy and safety of immunosuppressive pulse therapy in the treatment of paraquat poisoning. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(7):588-597.
[65]Yan YH, Shang PZ, Lu QJ, et al., 2012. Triptolide regulates T cell-mediated immunity via induction of CD11Clow dendritic cell differentiation. Food Chem Toxicol, 50(7):2560-2564.
[66]Yang YQ, Wu YF, Xu FF, et al., 2019. Tripterygium glycoside fraction n2: alleviation of DSS-induced colitis by modulating immune homeostasis in mice. Phytomedicine, 58: 152855.
[67]Yao JC, Jiang ZZ, Duan WG, et al., 2008. Involvement of mitochondrial pathway in triptolide-induced cytotoxicity in human normal liver L-02 cells. Biol Pharm Bull, 31(4):592-597.
[68]Yu XJ, Zhao Q, Zhang XX, et al., 2017. Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation. Oncotarget, 8(40):67300-67314.
[69]https://doi.org/10.18632/oncotarget.18619
[70]Zhang WD, 2007. Effect of triptolide combined with glycyrrhizin on collagen-induced arthritis in rats. PhD Thesis, China Academy of Chinese Medical Sciences, Beijing, China (in Chinese).
[71]Zhao DQ, Li SW, Liao T, et al., 2018. Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury. Am J Transplant, 18(5):1083-1095.
[72]Zhao JX, Di TT, Wang Y, et al., 2016. Multi-glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod-induced skin lesions through a STAT3-dependent mechanism involving the inhibition of Th17-mediated inflammatory responses. Int J Mol Med, 38(3):747-757.
[73]Zhou H, Guo W, Long C, et al., 2015. Triptolide inhibits proliferation of Epstein‒Barr virus-positive B lymphocytes by down-regulating expression of a viral protein LMP1. Biochem Biophys Res Commun, 456(3):815-820.
[74]Zhou XX, Liang MX, 2009. Study on the effect of Tripterygium wilfordii compatibility prescription on reproductive system of nephrotic female rats. Pharmacol Clin Chin Mat Med, 25(4):56-58 (in Chinese).
Open peer comments: Debate/Discuss/Question/Opinion
<1>